RADNOR, Pa., June 4, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care conditions, today announced that preclinical data presented at the American Society of Clinical Oncology (ASCO) annual meeting suggest that PMX-30063 has encouraging potential as a topical treatment for oral mucositis, a common and often debilitating complication from radiation and chemotherapy treatment. PMX-30063 is PolyMedix's first-in-class defensin-mimetic which recently demonstrated positive results in a Phase 2 clinical study as an intravenous treatment in patients with acute bacterial skin and skin structure Staphylococcus infections.